Navigation Links
Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
Date:4/15/2009

announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for fenretinide for the treatment of geographic atrophy associated with age-related macular degeneration.

"Our receipt of Fast Track designation has the potential to accelerate the development of fenretinide for the treatment of geographic atrophy, which is a condition without a currently approved treatment," said Barry Butler, CEO of Sirion Therapeutics. "The Fast Track designation combined with our positive interim analysis results gives Sirion a great deal of optimism that we will be able to bring a much needed treatment option to patients with geographic atrophy."

About Fast Track Designation

The Fast Track programs of the FDA are designed to facilitate the development of drugs that are intended to treat serious or life threatening conditions and that demonstrate the potential to address an unmet medical need for such a condition. Fast Track designation provides the option to submit a New Drug Application on a rolling basis, and thus enable the FDA to begin reviewing sections of the application before receiving the complete application. New Drug Applications for products with a Fast Track designation also generally receive a priority review designation, meaning the application will be reviewed in six months rather than the 10-month standard review time.

About Fenretinide

Fenretinide is an oral vitamin A binding protein antagonist being studied in patients with geographic atrophy (GA), the most advanced form of dry age-related macular degeneration (AMD). Fenretinide is believed to halt the accumulation of retinol (vitamin A) toxins through affinity for retinol-binding protein. It is also believed to slow the formation and accumulation of toxic byproducts thought to be responsible for vision loss in conditions such as GA.

About Geographic Atrophy

Geogra
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Amneal Pharmaceuticals is,pleased to announce that it ... USP in strengths of 5mg, 10mg, 25mg and ... an AA-Rated,therapeutically equivalent alternative to Urecholine(R) (a trademark ... breakthrough for Amneal, who is,one of the very ...
... Ill., Nov. 29 Abbott (NYSE:,ABT)announced today that ... Food and Drug Administration (FDA) recommended approval for ... V is a,next-generation drug eluting stent intended for ... The FDA advisory committee voted to recommend the ...
... (NYSE: BSX ) today welcomed the recommendation ... panel to approve with conditions the,PROMUS(TM) / XIENCE(TM) ... V stent systems are identical products, sold respectively,by ... stent,systems would be covered by the same FDA ...
... Nov. 29 As early detection and treatments,improve, ... Autism and,Asperger,s Syndrome are considering higher education., ... of an aging population,with autism, others have turned ... with Autism and Developmental Disabilities (AHEADD), to,enhance their ...
... 2007 Traditionally, clinicians have relied on information ... as the primary means of assessing patients symptoms ... arise if important symptoms go unreported during those ... new study by researchers at Memorial Sloan-Kettering Cancer ...
... Experts Address Smart Solutions to Keep Program,Accessible and Affordable, ... Medical Society hosted a panel discussion with local voters ... Medicare could,leave the program after scheduled pay cuts go ... people in the program to find a doctor. But ...
Cached Medicine News:Health News:FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Autism U: As College Application Deadlines Near, Growing Adult Autism Population Focuses on Higher Education 2Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
(Date:1/23/2015)... DES MOINES, Iowa , Jan. 23, 2015  The Partnership to ... Iowa health care leaders and a new study ... prescription medications. The PFCD is a nationwide coalition working to educate ... The research released at the Capitol was focused on how the ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: